Mentoring in Advanced mHealth Technologies and Machine Learning for HIV/Drug Abuse Research

指导艾滋病毒/药物滥用研究的先进移动医疗技术和机器学习

• 批准号: 10529984
• 负责人: Edward W Boyer
• 金额: $ 19.13万
• 依托单位: OHIO STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-11-19 至 2026-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10529984
• 关键词: Mentoring; Advanced; mHealth; Technologies; Machine

Abstract Renewal of my Midcareer Investigator Award in Patient-Oriented Research (K24) will allow me to continue my strong efforts directed toward successful original investigations and mentoring to generate research capacity in mobile technologies to improve health (mHealth). The impact of the initial K24 on my mentees has been striking. Since award of the initial K24, nearly two dozen of my mentees, 70% of whom are women or minorities, have been PI on NIH funded studies (under K, R, or Loan Repayment Program mechanisms). The impact the K24 on my own research has been substantial. Since 2014, I have been Principal Investigator (PI) on six federally funded awards: 1) one newly funded 4-year R01 from NIDA; 2) one R56 from NIDA; 3) one two-year R01 from NIDA; 4) one 4-year R01 from NIDA; 5) my K24 from NIDA; and 6) one newly funded 4-year DARPA research award. In addition, I received a William J Fulbright Foreign Scholarship to Malaysia. As my K24 evolved, so has my research focus. My overall research objective is to devote sufficient time to investigate use of next generation (“NextGen”) technologies, invisible biosensing, and machine learning in substance abuse and HIV research. My first research project, Virya, uses “digital phenotyping” with invisible biosensing and machine learning, to identify acute pain exacerbations in HIV+ individuals on opioids, a population at risk for problematic opioid use. The second reseach project uses mobile technologies to diagnose Covid-19 infection in HIV+ persons who inhale cannabis, itself a high-impact topic. Finally, the R01-funded MyTPill project compares the NextGen technology of unobtrusive ingestible biosensors that provide vivid, indisputable measures of medication ingestion. NextGen research discoveries become commercial products, but this process of introducing new discoveries into the healthcare economy remains deeply unfamiliar—yet increasingly important— to academic clinician-scientists. The objective of my Career Development Activities, therefore, involves learning how to navigate regulatory processes, FDA approvals, valuations, venture capital, contracts and intellectual property rights. Because of the growing importance of commercialization of research findings to the health and sustainability of academic careers, my overall mentoring objective of this K24 is to develop researchers who not only have the skills to conduct rigorous NextGen mHealth studies, but also to extend the mass of NIH-funded mHealth research into the healthcare economy. My mentoring approach incorporates several components that contributed to the success of my initial K24: dedicated funding for mentee’s early investigations; outstanding institutional support; several sources of referral of high-quality mentees; and renowned co- mentors who will help me establish a pipeline of mentees that have risen to that “cutting edge” where successful academic careers begin. This proposed K24 renewal, with its focus on NextGen technologies, invisible biosensing, and machine learning, is highly relevant to NIH’s mission because the lessons learned from this substance abuse and HIV research are directly applicable to the care of patients with common, intractable, and expensive conditions.

摘要 更新我的职业中期研究者奖以患者为导向的研究（K24）将使我能够继续我的努力 针对成功的原始调查和指导，以产生移动的技术的研究能力， 改善健康（mHealth）。最初的K24对我的学员的影响是惊人的。自从授予最初的K24以来， 我的学员中有近24人，其中70%是女性或少数民族，他们是NIH资助研究的PI（根据K，R， 或贷款偿还机制）。K24对我自己的研究产生了巨大的影响。自2014年以来，我 我是六个联邦资助奖项的首席研究员（PI）：1）一个来自NIDA的新资助的4年R 01; 2）一个R56 来自NIDA; 3）来自NIDA的一个两年R 01; 4）来自NIDA的一个4年R 01; 5）来自NIDA的我的K24;以及6）一个新资助的 4-年度DARPA研究奖此外，我还获得了William J Fulbright外国奖学金，前往马来西亚。作为我的K24 我的研究重点也在进化我的总体研究目标是投入足够的时间来研究next的使用 在药物滥用和艾滋病研究中，我们使用了新一代（“NextGen”）技术、隐形生物传感和机器学习。我 第一个研究项目Virya使用具有隐形生物传感和机器学习的“数字表型”来识别急性疼痛 使用阿片类药物的艾滋病毒阳性个体的病情加重，这是一个存在阿片类药物使用问题风险的人群。第二个研究项目 使用移动的技术来诊断吸入大麻的艾滋病毒阳性者的新型冠状病毒感染，这本身就是一个高影响力的话题。 最后，R 01资助的MyTPill项目比较了NextGen技术的不引人注目的可摄取生物传感器， 生动的无可争议的药物摄入量下一代研究发现成为商业产品，但这 将新发现引入医疗保健经济的过程仍然非常陌生，但越来越重要， to academic学术clinician临床-scientists科学家.因此，我的职业发展活动的目标包括学习如何 浏览监管流程、FDA批准、估值、风险投资、合同和知识产权。因为 研究成果的商业化对学术生涯的健康和可持续性越来越重要，我 该K24的总体指导目标是培养研究人员，他们不仅具有开展严格的下一代技术的技能， mHealth研究，但也将NIH资助的mHealth研究扩展到医疗保健经济中。我的指导 这种方法包含了几个组成部分，有助于我最初的K24的成功：为学员的 早期调查;出色的机构支持;高质量学员的几个转介来源;以及著名的共同 导师谁将帮助我建立一个管道的学员已经上升到“尖端”，成功的学术 职业生涯开始。此次提议的K24更新，重点关注下一代技术、隐形生物传感和机器 这与NIH的使命高度相关，因为从药物滥用和艾滋病毒研究中吸取的教训是 直接适用于常见、疑难、昂贵病症患者的护理。